Clinical Trials Browser

Multiple Myeloma, Recurrence

Prostatic Neoplasms

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Prostatic Neoplasms, Castration-Resistant

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

Multiple Myeloma

Burkitt Lymphoma

Multiple Myeloma, Neoplasms, Plasma Cell

Multiple Myeloma, Recurrence

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Fallopian Tube Neoplasms, Ovarian Neoplasms

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Prostate Cancer Metastatic

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma, Neoplasms

Metastatic Castration-Resistant Prostate Cancer

Multiple Myeloma, Neoplasms

Multiple Myeloma, Neoplasms, Plasma Cell

Neoplasm Metastasis, Prostatic Neoplasms

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

Multiple Myeloma, Recurrence

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Multiple Myeloma

Clinical Trials

SUCCESSOR-1

MK-5684-004

CERVINO

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

CEVOLUTION

MK-3475-06B

MK-5684-01A

MK-3475-01E

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

MK-1045-005

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma

MagnetisMM-6

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

A Study of Daratumumab

MajesTEC-7

TroFuse-022

iMMagine-3

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

MAGNETISMM-5

OMAHA-003

PLYCOM

DURGA-4

DREAMM-10

A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

MonumenTAL-6

MOMENTUM

LINKER-MM3

A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

KEYNOTE-365

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.

A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

FUMANBA-03

A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients

Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)